Dr. Ehab H Shaker, MD
Claim this profileNational Cancer Institute
Studies Sepsis
Studies Anosognosia
4 reported clinical trials
10 drugs studied
More about Ehab H Shaker, MD
Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 0 Active Clinical TrialsTreatments Ehab H Shaker, MD has experience with
- Dexmedetomidine 1
- Dexmedetomidine 2
- Tramal 1
- Tramal 2
- Bupivacaine
- Dexmedetomidine
Breakdown of trials Ehab H Shaker, MD has run
Sepsis
Chronic chest pain
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ehab H Shaker, MD specialize in?
Ehab H Shaker, MD focuses on Sepsis and Anosognosia. In particular, much of their work with Sepsis has involved treating patients, or patients who are undergoing treatment.
Is Ehab H Shaker, MD currently recruiting for clinical trials?
No, Ehab H Shaker, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Ehab H Shaker, MD has studied deeply?
Yes, Ehab H Shaker, MD has studied treatments such as Dexmedetomidine 1, Dexmedetomidine 2, Tramal 1.
What is the best way to schedule an appointment with Ehab H Shaker, MD?
Apply for one of the trials that Ehab H Shaker, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.